Cristiano Ronaldo Takes Home Alipay Top Scorer Trophy at UEFA EURO 2020
12.7.2021 05:08:00 EEST | Business Wire | Press release
Portuguese football star Cristiano Ronaldo today became the winner of the Gold Trophy of the Alipay Top Scorer Awards at UEFA EURO 2020. Regarded as one of the greatest footballers of all time, Ronaldo netted five goals and made one assist at the competition. Patrik Schick from the Czech Republic was awarded the Silver Trophy, scoring five goals, while France’s Karim Benzema was the recipient of the Bronze Trophy, netting four goals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210711005035/en/
Portuguese football star Cristiano Ronaldo became the winner of the Gold Trophy of the Alipay Top Scorer Awards at UEFA EURO 2020. (Photo: Business Wire)
The Alipay Top Scorer trophies are the first major international football Top-Scorer trophies to embed blockchain in their design, incorporating a hash code at the base through which scoring records of the tournament’s top three scorers can be uploaded and permanently stored on a blockchain powered by AntChain. Using the hash code provided, Alipay will upload the trophy data to the blockchain, ensuring a permanent, immutable record of the top scorers’ achievements.
“Our warmest congratulations to Cristiano Ronaldo for his phenomenal performances at UEFA EURO 2020, and for winning the Alipay Top Scorer Gold Award,” said Eric Jing, Chairman and CEO of Ant Group, who presented the top scorer trophies via video from Hangzhou immediately after the final game of UEFA EURO 2020. “Just as we have used blockchain technology to permanently preserve the wonderful scoring moments of the top scorers like him, we will also keep working with UEFA, to explore innovative digital solutions that improve fans’ experiences while enjoying football.”
UEFA and AntChain, one of the technology brands of Ant Group, on June 10 announced a five-year global partnership to jointly explore using blockchain technology to accelerate the digital transformation of the football industry and improve the experiences of fans across the globe. Under the agreement, AntChain became the official global blockchain partner of UEFA EURO 2020.
To honor the performances of the top scoring players, an AntChain-developed digital record of highlights from the UEFA EURO 2020 top scorers will be preserved at UEFA’s headquarters, making it the first digital collectible in the history of the EURO Top Scorer.
“The top scoring moments digital collectible will serve as a lasting memento, encouraging football fans around the world to spread the team spirit and happiness that are part and parcel of this beloved sport,” said Mr. Jing.
The UEFA EURO 2020 Top Scorer trophies are designed by Alipay, the world’s leading digital payment and lifestyle platform operated by Ant Group, which has been UEFA’s global partner since November 2018.
On June 12, UEFA launched a new mini program with Alipay to improve engagement with mobile-savvy Chinese football fans. Dubbed the UEFA EURO 2020 Official Digital Hub, the mini program offers football fans across China an inside look at the tournament through regular news updates, interviews with key players, and much more. The UEFA mini program has rapidly become the most popular sports-focused mini program on Alipay, attracting over 12 million users as of July 11.
During the tournament, Alipay launched a campaign via the UEFA EURO 2020 Dream Tour mini program that enables authenticated users to earn points by engaging in various fan activities. Powered by AntChain's technologies, the top 1,600 users will receive gold, silver, and bronze digital trophies as a form of digital souvenir with certificates on a blockchain.
Alipay also launched "Top Scorers on Campus,” a new advocacy program dedicated to supporting the development of campus football in China. To inspire more teenagers to pursue their football dreams, the program will award trophies with the same design as the Alipay Top Scorer Gold Trophy of the UEFA EURO 2020 to the best young players in campus football tournaments across China. Similar to the UEFA EURO 2020 Top Scorer Trophy, these students’ scoring records and achievements will also be stored on a blockchain provided by AntChain.
About AntChain
AntChain is one of Ant Group’s technology brands. According to IPR Daily and patent database IncoPat, Ant Group held the highest number of published blockchain-related patent applications between 2017 and the six months ended June 30, 2020. Since the launch of Ant Group’s blockchain business in 2016, the company has pioneered the use of AntChain in over 50 blockchain commercial applications and use cases, including supply chain finance, cross-border remittance, charitable donations, and product provenance.
About Alipay
Alipay is the leading digital payment platform in China, serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.
Ant Group has further introduced Alipay+, the global cross-border mobile payments and marketing solution which enables merchants, especially small and medium-sized businesses, to better serve consumers from all over the world by collaborating with global partners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210711005035/en/
Contact information
For media enquiries
Ant Group
Vick Li Wei
Email: vick.lw@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom